Performance Indicators

 

Performance Indicators Commentary

The 2019 performance indicators for the registries of the UKIACR are available here.

You can click on the various tabs to view the corresponding comparison tables. You can use the search box above the table to filter it, or click on any column in the table to sort by it (if applicable). Please read the notes under each table, as sometimes the data is not directly comparable.

A detailed commentary of the findings for each registry may be found at this link.

An Excel download of the complete results tables may be found at this link.

Old Performance Indicators Reports

Reports are also available for preceding years. Use the links below to access these reports:

Executive summary
Target not reached or not in line with other registries
Target attained
Indicator Country average (population) Country average (country) England Scotland Wales Northern Ireland
Stability: Percentage change (%) for all cancers (C00-C97 ex. C44) in 2017 compared with 2014-20161 0.2% 0.0% 0.3% -0.8% -0.3% 0.6%
Registry Creep: Percentage (%) for all cancers (C00-C97 ex. C44) of 2016 registrations between 02/02/2019 to 01/03/2019 compared with registrations at 31/01/20187. 1.6% 2.4% 1.4% 4.0% 1.6% 2.6%
Staging: Proportion (%) of all cases (C00-C97 ex. C44) with valid known stage registered out of all 2017 registered cancers (C00-C97 ex. C44)2 80.6% 78.6% 81.9% 67.5% 79.7% 85.3%
Average of Core Patient Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with demographic information3 98.6% 96.9% 99.3% 96.5% 91.9% 100.0%
Average of Core Tumour Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with tumour information4 97.3% 96.9% 97.4% 96.1% 97.1% 97.2%
Diagnosing Hospital Known: Percentage (%) of all cancers (C00-C97 ex. C44) registered with an organisation of diagnosis 97.7% 96.9% 98.2% 93.0% 98.2% 98.1%
Death Certificate Only (DCO) Rates: Percentage (%) of all cancers (C00-C97 ex. C44) registered as a DCO5 0.6% 0.6% 0.6% 0.2% 1.3% 0.3%
Zero Day Survivors: Percentage (%) of all cancers (C00-C97 ex. C44) registered with the date of death equals the date of diagnosis5 1.2% 1.0% 1.3% 0.5% 1.6% 0.6%
Microscopically Verified: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified 84.8% 84.3% 85.1% 82.1% 83.4% 86.3%
Non Specific Codes: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified with non specific morphology codes 1.2% 1.3% 1.2% 1.1% 1.5% 1.6%
Grade: Percentage (%) of all cancers (C00-C97 ex. C44) registered with a known grade 59.6% 61.3% 59.4% 59.0% 61.1% 65.6%
Treatment: Percentage (%) of all cancers (C00-C97 ex. C44) registered with any treatment 86.6% 78.4% 89.2% 68.0% 84.8% 71.9%
Breast Screening Data: Percentage of breast cancer (C50) cases from 2016 screen detected for ages 50-646 42.2% 48.2% 40.8% 48.0% 55.8% NA
Cervical Screening Data: Percentage of cervical cancer (C53) cases from 2016 screen detected for ages 25-606 28.6% 38.0% 25.6% 50.4% NA NA
Bowel Screening Data: Percentage of bowel cancer (C18-C20) cases from 2016 screen detected for ages 60-696 4.4% 19.2% 0.0% 29.2% 28.4% NA
  1. Data for Wales is for 2016 throughout unless otherwise specified (here 2016 compared with 2013-2015)
  2. Staging target: > 70%
  3. Core Patient information includes name, address, postcode, sex, date of birth, ethnicity, date of death, unique health identifier
  4. Core Tumour information includes date of diagnosis, site of primary growth, type of growth, behaviour of growth, basis of diagnosis, hospital of diagnosis
  5. DCO and zero survivor rate targets: <2%
  6. Screening data for Wales is for 2015
  7. England & Wales 02/02/2019, Scotland 01/03/2019 & Northern Ireland 28/02/2019
NA – not available (average excludes corresponding country)

Registrations and Timeliness
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
2014 363545 90886 301897 32747 19690 9211
2015 366439 91610 304784 32464 19705 9486
2016 368620 92155 307312 32294 19316 9698
2016 (from Previous PI) 362577 90644 303137 30989 19004 9447
No. of 2017 not-finalised cases 338 85 328 4 6 0
No. of 2017 full cases 366957 91739 305688 32234 19514 9521
Registry creep 1.6% 2.4% 1.4% 4.0% 1.6% 2.6%
Not-finalised cases 0.09 0.04 0.11 0.01 0.03 0.00

No. of Cases (current year) and percentage change vs. previous year (persons)
Statistically significant difference in 2017 compared to 2014-2016
No statistical significant difference in 2017 compared to 2014-2016
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 366,957 (0.2%) 0.0% 305688 (0.3%) 32234 (-0.8%) 19514 (-0.3%) 9521 (0.6%)
All xnmsc 0-24 3,740 (-7.1%) -6.8% 3169 (-6.9%) 295 (-6.8%) 160 (-17.4%) 116 (3.9%)
All xnmsc 25-59 85,863 (0.9%) 0.9% 71854 (1.2%) 7443 (-1.9%) 4099 (0.6%) 2467 (3.7%)
All xnmsc 60-79 196,889 (1%) 0.7% 163098 (1.1%) 17767 (0.4%) 10956 (1%) 5068 (0.5%)
All xnmsc 80+ 80,465 (-2.1%) -2.8% 67567 (-1.9%) 6729 (-2.4%) 4299 (-3.6%) 1870 (-3.1%)
All registrations 602,303 (0.3%) 2.7% 498608 (-0.2%) 52239 (-3.3%) 34315 (16.1%) 17141 (-1.7%)
Haematology 32,648 (-0.1%) -3.0% 27902 (0.9%) 2383 (-4.7%) 1516 (-12.1%) 847 (3.8%)
Head and Neck 12,273 (2.5%) 2.9% 9946 (2.5%) 1271 (0.4%) 714 (5%) 342 (3.6%)
Lower GI 45,344 (0.1%) 0.3% 37524 (0%) 4079 (1.1%) 2494 (-0.5%) 1247 (0.3%)
Upper GI 15,571 (-1.8%) -2.5% 12712 (-2%) 1586 (2.1%) 858 (-4.4%) 415 (-5.6%)
HPB 18,710 (1.8%) -1.5% 15651 (2.8%) 1622 (-4.3%) 968 (-0.3%) 469 (-4.1%)
Trachea, Bronchus & Lung 48,082 (1%) 0.7% 38906 (1.1%) 5331 (0.3%) 2555 (2.6%) 1290 (-1.3%)
Melanoma of skin 16,156 (1.2%) -3.2% 13740 (2.3%) 1226 (-8.4%) 846 (4.6%) 344 (-11.1%)
Breast 55,197 (-0.2%) 1.0% 46109 (-0.4%) 4737 (0.9%) 2854 (-2.3%) 1497 (6%)
Cervix 3,103 (-2.9%) -9.3% 2591 (0.3%) 276 (-25.6%) 170 (7.1%) 66 (-19.2%)
Other Female Genitals 18,629 (0%) -0.5% 15435 (-0.1%) 1681 (2.6%) 1010 (-2.8%) 503 (-1.8%)
Prostate 48,638 (0.9%) 2.1% 41201 (0.4%) 3518 (4.2%) 2782 (6.1%) 1137 (-2.2%)
Kidney 12,745 (-0.9%) 3.2% 10586 (-1.6%) 1150 (-0.1%) 622 (4.2%) 387 (10.5%)
Bladder 10,295 (0.2%) -0.3% 8686 (0.8%) 830 (-4%) 548 (-5.7%) 231 (7.6%)
Brain and CNS 5,676 (1.6%) 2.5% 4769 (1.3%) 464 (4.9%) 294 (0.7%) 149 (3%)
Thyroid & other endocrine glands 4,080 (4.9%) 12.6% 3499 (4.8%) 303 (-5.9%) 136 (0.2%) 142 (51.1%)
CUP 8,420 (-4.8%) -4.3% 6892 (-5.1%) 782 (-8.7%) 577 (8.5%) 169 (-12%)
Other invasive cancer 11,390 (-2%) -4.3% 9539 (-1%) 995 (-8.2%) 570 (-7.1%) 286 (-1%)
Breast in situ 8,272 (4.1%) 11.0% 7049 (2.8%) 478 (-2.2%) 499 (32.2%) 246 (11.3%)
Cervix in situ 25,297 (-15.5%) -21.9% 20978 (-14%) 2319 (-10.4%) 1213 (-35.2%) 787 (-27.9%)
Other tumours 50,070 (-0.7%) -6.8% 38576 (2.2%) 6074 (-7.7%) 2638 (-15.4%) 2782 (-6.2%)
Other non-melanoma skin cancer 1903 (-3%) -10.0% 1573 (9.1%) 156 (-9.8%) 114 (-61.7%) 60 (22.4%)
Basal cell carcinoma 113098 (2.8%) 53.3% 94773 (-1.8%) 7727 (-8%) 7924 (221.7%) 2674 (1.4%)
Squamous cell carcinoma 36706 (7.5%) 10.5% 29971 (7%) 3251 (-0.9%) 2413 (29.5%) 1071 (6.4%)

Percentage (%) of death certificate only cases (persons) for 2017
A statistic highlighted in red means that the target was not reached or was not in line with other registries
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 0.6% 0.6% 0.6% 0.2% 1.3% 0.3%
All xnmsc 0-24 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
All xnmsc 25-59 0.1% 0.2% 0.1% 0.1% 0.3% 0.1%
All xnmsc 60-79 0.3% 0.3% 0.3% 0.1% 0.8% 0.2%
All xnmsc 80+ 1.8% 1.7% 1.8% 0.4% 3.6% 1.0%
All registrations 0.4% 0.4% 0.4% 0.1% 0.8% 0.2%
Haematology 0.8% 0.6% 0.8% 0.1% 1.1% 0.4%
Head and Neck 0.2% 0.1% 0.2% 0.0% 0.3% 0.0%
Lower GI 0.4% 0.5% 0.4% 0.1% 1.0% 0.3%
Upper GI 0.5% 0.7% 0.4% 0.1% 2.1% 0.0%
HPB 1.0% 1.2% 1.0% 0.1% 2.8% 0.9%
Trachea, Bronchus & Lung 0.6% 0.7% 0.5% 0.2% 1.8% 0.5%
Melanoma of skin 0.1% 0.0% 0.1% 0.0% 0.1% 0.0%
Breast 0.2% 0.2% 0.2% 0.1% 0.5% 0.1%
Cervix 0.3% 0.2% 0.3% 0.0% 0.6% 0.0%
Other Female Genitals 0.4% 0.5% 0.4% 0.2% 0.8% 0.6%
Prostate 0.5% 0.3% 0.5% 0.1% 0.8% 0.1%
Kidney 0.4% 0.5% 0.4% 0.2% 1.4% 0.0%
Bladder 0.7% 0.6% 0.7% 0.0% 1.5% 0.4%
Brain and CNS 0.4% 0.4% 0.4% 0.2% 1.0% 0.0%
Thyroid & other endocrine glands 0.2% 0.3% 0.2% 0.3% 0.0% 0.7%
CUP 4.0% 4.0% 3.9% 2.3% 8.1% 1.8%
Other invasive cancer 1.1% 1.3% 1.0% 0.9% 2.3% 1.0%
Breast in situ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cervix in situ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other tumours 0.5% 0.5% 0.6% 0.0% 1.2% 0.1%

Percentage (%) of zero survival cases (persons)
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 1.2% 1.0% 1.3% 0.5% 1.6% 0.6%
All xnmsc 0-24 0.2% 0.1% 0.2% 0.0% 0.0% 0.0%
All xnmsc 25-59 0.3% 0.4% 0.3% 0.3% 0.4% 0.4%
All xnmsc 60-79 0.8% 0.7% 0.9% 0.4% 1.0% 0.4%
All xnmsc 80+ 3.0% 2.5% 3.2% 1.0% 4.1% 1.5%
All registrations 0.8% 0.6% 0.8% 0.3% 1.0% 0.3%
Haematology 1.4% 1.0% 1.5% 0.4% 1.6% 0.6%
Head and Neck 0.4% 0.3% 0.4% 0.2% 0.4% 0.0%
Lower GI 1.1% 0.9% 1.1% 0.4% 1.3% 0.6%
Upper GI 1.3% 1.1% 1.4% 0.4% 2.4% 0.2%
HPB 2.4% 2.0% 2.5% 0.7% 3.2% 1.7%
Trachea, Bronchus & Lung 1.9% 1.4% 2.1% 0.6% 2.1% 0.7%
Melanoma of skin 0.1% 0.1% 0.1% 0.0% 0.1% 0.0%
Breast 0.3% 0.3% 0.3% 0.1% 0.5% 0.2%
Cervix 0.3% 0.2% 0.3% 0.0% 0.6% 0.0%
Other Female Genitals 0.9% 0.8% 0.9% 0.4% 0.9% 1.0%
Prostate 0.6% 0.5% 0.7% 0.2% 0.8% 0.2%
Kidney 1.2% 0.8% 1.3% 0.3% 1.4% 0.3%
Bladder 1.2% 0.9% 1.3% 0.1% 1.5% 0.9%
Brain and CNS 0.6% 0.6% 0.7% 0.2% 1.4% 0.0%
Thyroid & other endocrine glands 0.5% 0.6% 0.5% 1.0% 0.0% 0.7%
CUP 6.7% 5.8% 7.0% 3.8% 8.8% 3.6%
Other invasive cancer 2.1% 2.2% 2.0% 1.5% 3.2% 2.1%
Breast in situ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cervix in situ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other tumours 0.8% 0.6% 0.9% 0.1% 1.2% 0.1%

Percentage (%) of microscopically verified cases (persons)
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 84.8% 84.3% 85.1% 82.1% 83.4% 86.3%
All xnmsc 0-24 93.6% 92.7% 93.6% 96.6% 85.0% 95.7%
All xnmsc 25-59 96.2% 96.1% 96.3% 95.8% 95.3% 97.1%
All xnmsc 60-79 88.6% 87.7% 89.0% 85.8% 87.2% 88.6%
All xnmsc 80+ 62.8% 62.0% 63.5% 56.4% 62.4% 65.5%
All registrations 89.6% 89.4% 89.7% 88.1% 88.9% 90.9%
Haematology 87.4% 89.1% 86.9% 95.9% 80.8% 92.9%
Head and Neck 97.5% 97.8% 97.6% 96.3% 98.3% 99.1%
Lower GI 88.6% 88.5% 88.8% 86.7% 88.5% 90.1%
Upper GI 92.9% 92.4% 93.2% 91.7% 91.7% 93.0%
HPB 52.2% 51.2% 53.2% 41.7% 47.5% 62.5%
Trachea, Bronchus & Lung 68.9% 67.4% 69.7% 63.1% 68.9% 68.0%
Melanoma of skin 99.6% 99.7% 99.6% 99.8% 99.3% 100.0%
Breast 98.7% 98.7% 98.7% 98.7% 98.1% 99.4%
Cervix 97.8% 98.3% 97.8% 97.8% 97.6% 100.0%
Other Female Genitals 94.6% 94.1% 94.9% 92.7% 93.0% 96.0%
Prostate 85.7% 85.5% 85.8% 82.5% 87.4% 86.3%
Kidney 74.2% 73.4% 74.5% 72.8% 69.6% 76.7%
Bladder 90.1% 90.1% 90.3% 87.0% 90.3% 92.6%
Brain and CNS 70.3% 66.3% 71.1% 70.7% 59.5% 63.8%
Thyroid & other endocrine glands 97.1% 96.0% 97.3% 95.4% 94.1% 97.2%
CUP 45.3% 42.0% 46.2% 40.0% 44.7% 37.3%
Other invasive cancer 86.2% 84.1% 86.9% 80.8% 83.2% 85.7%
Breast in situ 99.9% 100.0% 99.9% 100.0% 100.0% 100.0%
Cervix in situ 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Other tumours 87.8% 87.8% 87.4% 92.5% 80.0% 91.0%
Percentage (%) of non-specificity of morphology codes for cases which are microscopically verified
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 1.2% 1.3% 1.2% 1.1% 1.5% 1.6%
All xnmsc 0-24 0.5% 0.7% 0.4% 0.7% 0.7% 0.9%
All xnmsc 25-59 0.8% 0.7% 0.8% 0.6% 0.6% 0.6%
All xnmsc 60-79 1.1% 1.2% 1.1% 1.0% 1.3% 1.5%
All xnmsc 80+ 2.4% 3.0% 2.4% 2.2% 3.2% 4.1%
All registrations 0.9% 1.3% 0.9% 0.9% 0.9% 2.6%
Haematology 0.8% 0.7% 0.8% 0.3% 0.7% 0.9%
Head and Neck 0.9% 1.1% 0.9% 0.8% 0.7% 2.1%
Lower GI 0.7% 0.6% 0.7% 0.2% 1.2% 0.3%
Upper GI 1.2% 1.2% 1.1% 1.9% 0.6% 1.3%
HPB 5.0% 6.1% 4.8% 4.1% 6.7% 8.5%
Trachea, Bronchus & Lung 2.1% 2.4% 2.1% 1.9% 2.7% 3.1%
Melanoma of skin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Breast 0.9% 1.0% 0.9% 1.1% 0.7% 1.2%
Cervix 0.6% 0.3% 0.7% 0.4% 0.0% 0.0%
Other Female Genitals 0.9% 1.0% 0.9% 1.2% 1.4% 0.6%
Prostate 0.5% 0.3% 0.6% 0.0% 0.7% 0.1%
Kidney 1.1% 1.6% 1.1% 0.5% 1.4% 3.4%
Bladder 0.6% 0.6% 0.6% 0.4% 0.6% 0.9%
Brain and CNS 0.2% 0.1% 0.2% 0.0% 0.0% 0.0%
Thyroid & other endocrine glands 1.8% 2.0% 1.8% 1.7% 3.9% 0.7%
CUP 16.9% 19.6% 16.6% 16.6% 18.2% 27.0%
Other invasive cancer 0.8% 1.0% 0.8% 1.0% 0.8% 1.2%
Breast in situ 0.1% 0.1% 0.1% 0.4% 0.0% 0.0%
Cervix in situ 0.1% 0.1% 0.1% 0.0% 0.1% 0.3%
Other tumours 2.4% 4.0% 1.9% 1.8% 1.7% 10.5%

Mortality : Incidence ratios (2017)
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 0.45 0.46 0.44 0.50 0.45 0.46
All xnmsc 0-24 0.13 0.13 0.13 0.13 0.16 0.12
All xnmsc 25-59 0.23 0.24 0.23 0.26 0.25 0.23
All xnmsc 60-79 0.42 0.44 0.41 0.47 0.42 0.46
All xnmsc 80+ 0.78 0.79 0.77 0.85 0.74 0.78
All registrations 0.28 0.30 0.28 0.32 0.27 0.33
Haematology 0.41 0.42 0.40 0.48 0.44 0.37
Head and Neck 0.33 0.38 0.32 0.41 0.30 0.48
Lower GI 0.39 0.42 0.38 0.44 0.38 0.47
Upper GI 0.78 0.79 0.78 0.80 0.80 0.78
HPB 0.86 0.89 0.85 0.94 0.85 0.94
Trachea, Bronchus & Lung 0.73 0.77 0.72 0.76 0.77 0.84
Melanoma of skin 0.15 0.16 0.14 0.15 0.16 0.19
Breast 0.20 0.19 0.21 0.20 0.19 0.17
Cervix 0.27 0.30 0.26 0.38 0.25 0.30
Other Female Genitals 0.38 0.39 0.38 0.42 0.38 0.39
Prostate 0.25 0.24 0.25 0.28 0.21 0.20
Kidney 0.34 0.35 0.34 0.37 0.34 0.35
Bladder 0.55 0.57 0.55 0.57 0.59 0.55
Brain and CNS 0.77 0.78 0.76 0.84 0.71 0.79
Thyroid & other endocrine glands 0.13 0.12 0.13 0.14 0.15 0.06
CUP 1.09 1.04 1.10 1.03 1.05 0.98
Other invasive cancer 0.77 0.71 0.78 0.73 0.78 0.56
Breast in situ 0.00 0.02 0.00 0.00 0.00 0.07
Cervix in situ 0.00 0.00 0.00 0.00 0.00 0.01
Other tumours 0.09 0.12 0.08 0.05 0.09 0.25

Completeness of the dataset (%) - demographics and diagnostic details
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
Patient's name 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Patient's address 99.7% 99.9% 99.6% 100.0% 99.9% 100.0%
Sex 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Ethnicity 89.5% 67.3% 94.8% 72.0% 35.2% NA
Date of death (where dead) 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Postcode 100.0% 100.0% 100.0% 100.0% 99.9% 100.0%
Date of birth 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Unique health identifier 99.9% 100.0% 99.9% 100.0% 100.0% 100.0%
Anniversary (diagnosis) date 99.9% 100.0% 99.9% 100.0% 100.0% 100.0%
Site of primary growth 97.6% 97.6% 97.7% 97.4% 97.0% 98.2%
Type of growth 89.0% 87.9% 89.3% 86.5% 88.1% 87.6%
Behaviour of growth 99.9% 99.8% 100.0% 99.6% 99.9% 99.8%
Basis of diagnosis 99.5% 99.5% 99.5% 100.0% 99.1% 99.5%
Diagnosis with hospital 97.7% 96.9% 98.2% 93.0% 98.2% 98.1%

% of all cancer cases (xnmsc)
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
Treatment 86.6% 78.4% 89.2% 68.0% 84.8% 71.9%
No Treatment 5.5% 16.3% 2.1% 31.9% 3.2% 28.1%
Stage I and II patients receiving any treatment (%) 90.5% 78.3% 95.9% 83.6% 51.5% 82.1%

% of Cases treated with Surgery
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 48.7% 47.2% 49.6% 40.1% 48.1% 50.8%
All xnmsc 0-24 51.7% 52.4% 51.8% 47.8% 50.6% 59.5%
All xnmsc 25-59 66.1% 64.5% 66.8% 59.1% 68.0% 64.2%
All xnmsc 60-79 48.7% 46.5% 49.8% 39.2% 47.3% 49.7%
All xnmsc 80+ 30.1% 29.7% 30.8% 21.4% 31.2% 35.5%
Haematology 6.5% 7.7% 6.4% 5.8% 6.6% 11.9%
Head and Neck 54.0% 52.6% 55.0% 43.3% 59.9% 52.3%
Lower GI 67.5% 68.4% 67.8% 59.6% 71.3% 75.0%
Upper GI 36.9% 36.7% 38.7% 17.6% 37.9% 52.8%
HPB 32.1% 29.6% 34.0% 10.2% 32.2% 41.8%
Trachea, Bronchus & Lung 26.1% 22.8% 28.1% 13.1% 21.1% 28.8%
Melanoma of skin 96.7% 90.8% 97.2% 96.7% 97.9% 71.5%
Breast 76.4% 77.3% 76.4% 74.5% 79.0% 79.2%
Cervix 63.4% 58.8% 64.8% 53.6% 60.6% 56.1%
Other Female Genitals 75.8% 73.7% 76.7% 68.0% 76.6% 73.6%
Prostate 22.4% 16.8% 23.7% 13.9% 17.5% 12.0%
Kidney 59.8% 59.7% 60.7% 48.3% 59.6% 70.0%
Bladder 85.6% 85.2% 86.0% 79.9% 85.4% 89.6%
Brain and CNS 51.4% 50.3% 52.0% 47.6% 43.9% 57.7%
Thyroid & other endocrine glands 87.5% 84.2% 88.3% 80.5% 89.0% 78.9%
CUP 13.2% 11.6% 14.1% 4.7% 12.7% 14.8%
Other invasive cancer 56.7% 53.2% 58.1% 45.6% 53.0% 55.9%
Breast in situ 87.0% 87.7% 86.7% 91.8% 87.0% 85.4%
Cervix in situ 88.0% 70.4% 90.1% 98.3% 79.7% 13.5%
Other tumours 63.0% 60.4% 63.0% 71.1% 58.8% 48.8%
Non-Melanoma Skin Cancer 50.1% 55.5% 47.5% 91.5% 39.5% 43.6%

% of Cases treated with Radiotherapy
UKIACR average (population) UKIACR average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 20.9% 20.3% 21.0% 19.5% 20.5% 20.3%
All xnmsc 0-24 15.5% 15.2% 15.5% 16.6% 13.1% 15.5%
All xnmsc 25-59 24.5% 24.9% 24.4% 24.2% 26.3% 24.5%
All xnmsc 60-79 23.0% 22.0% 23.3% 21.2% 22.0% 21.4%
All xnmsc 80+ 12.0% 11.3% 12.2% 10.0% 11.4% 11.6%
Haematology 9.2% 9.0% 9.3% 7.8% 7.5% 11.6%
Head and Neck 59.3% 57.1% 60.7% 47.5% 60.5% 59.6%
Lower GI 13.3% 13.5% 13.2% 14.3% 12.2% 14.4%
Upper GI 18.5% 16.2% 19.0% 16.1% 21.4% 8.2%
HPB 2.4% 2.9% 2.4% 1.7% 2.9% 4.7%
Trachea, Bronchus & Lung 26.8% 26.6% 26.7% 26.9% 28.4% 24.6%
Melanoma of skin 0.7% 0.6% 0.8% 0.3% 0.6% 0.9%
Breast 38.0% 37.7% 37.9% 39.5% 38.7% 34.8%
Cervix 42.1% 47.8% 41.1% 45.7% 45.3% 59.1%
Other Female Genitals 16.1% 17.2% 15.8% 15.8% 20.5% 16.9%
Prostate 19.3% 14.8% 20.8% 7.0% 12.3% 19.2%
Kidney 5.4% 6.5% 5.3% 4.8% 7.1% 9.0%
Bladder 17.7% 16.9% 17.9% 16.5% 17.3% 16.0%
Brain and CNS 48.2% 45.2% 49.0% 45.5% 43.5% 43.0%
Thyroid & other endocrine glands 32.3% 28.9% 33.4% 22.1% 39.7% 20.4%
CUP 11.5% 10.1% 11.8% 9.7% 11.8% 7.1%
Other invasive cancer 15.2% 14.4% 15.3% 14.5% 16.3% 11.5%
Breast in situ 32.7% 35.8% 32.1% 39.7% 30.3% 41.1%
Cervix in situ 0.0% 0.1% 0.0% 0.0% 0.2% 0.0%
Other tumours 1.1% 1.3% 1.2% 0.3% 1.4% 2.4%
Non-Melanoma Skin Cancer 1.8% 1.1% 2.0% 0.4% 1.1% 0.8%

% of Cases treated with Teletherapy
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 19.8% 20.5% 19.8% NA 19.5% 22.3%
All xnmsc 0-24 12.5% 12.9% 12.5% NA 10.6% 15.5%
All xnmsc 25-59 22.7% 23.9% 22.6% NA 24.6% 24.5%
All xnmsc 60-79 21.9% 21.5% 22.0% NA 21.1% 21.4%
All xnmsc 80+ 11.8% 11.5% 11.8% NA 11.1% 11.6%
Haematology 9.0% 9.3% 9.1% NA 7.4% 11.6%
Head and Neck 60.1% 59.7% 60.2% NA 59.4% 59.6%
Lower GI 12.9% 13.0% 12.9% NA 11.6% 14.4%
Upper GI 18.1% 15.8% 18.3% NA 21.0% 8.2%
HPB 2.1% 3.1% 1.9% NA 2.7% 4.7%
Trachea, Bronchus & Lung 26.4% 26.4% 26.3% NA 28.2% 24.6%
Melanoma of skin 0.8% 0.7% 0.8% NA 0.6% 0.9%
Breast 37.6% 37.0% 37.6% NA 38.6% 34.8%
Prostate 40.9% 47.3% 40.3% NA 42.4% 59.1%
Cervix 9.2% 13.1% 8.7% NA 13.7% 16.9%
Other Female Genitals 18.6% 16.5% 19.0% NA 11.9% 18.5%
Kidney 5.3% 7.1% 5.1% NA 7.1% 9.0%
Bladder 17.6% 16.9% 17.7% NA 17.0% 16.0%
Brain and CNS 48.0% 44.7% 48.5% NA 42.5% 43.0%
Thyroid & other endocrine glands 8.8% 15.1% 8.0% NA 16.9% 20.4%
CUP 11.5% 10.2% 11.6% NA 11.8% 7.1%
Other invasive cancer 11.6% 11.1% 11.7% NA 10.0% 11.5%
Breast in situ 32.3% 34.3% 32.1% NA 29.9% 41.1%
Cervix in situ 0.0% 0.1% 0.0% NA 0.2% 0.0%
Other tumours 1.1% 1.5% 0.9% NA 1.3% 2.4%
Non-Melanoma Skin Cancer 1.8% 1.3% 1.9% NA 1.1% 0.8%

% of Cases treated with Chemotherapy
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 27.4% 25.5% 27.9% 24.6% 26.7% 22.9%
All xnmsc 0-24 64.5% 60.4% 65.3% 63.7% 61.9% 50.9%
All xnmsc 25-59 41.5% 41.0% 41.5% 41.8% 42.3% 38.4%
All xnmsc 60-79 28.2% 25.5% 28.9% 24.0% 27.6% 21.4%
All xnmsc 80+ 8.8% 6.9% 9.2% 5.5% 8.3% 4.8%
Haematology 54.1% 47.0% 55.0% 56.1% 51.6% 25.3%
Head and Neck 30.4% 27.3% 31.2% 25.3% 33.6% 19.0%
Lower GI 33.9% 32.3% 34.3% 31.5% 34.2% 29.3%
Upper GI 40.7% 40.9% 41.3% 34.5% 40.0% 47.7%
HPB 25.7% 23.4% 26.7% 15.9% 24.3% 26.9%
Trachea, Bronchus & Lung 26.9% 23.9% 28.2% 18.3% 28.4% 20.9%
Melanoma of skin 1.3% 1.4% 1.4% 0.3% 2.0% 1.7%
Breast 32.6% 32.0% 32.8% 30.8% 32.3% 32.1%
Cervix 38.0% 42.4% 37.1% 42.8% 41.2% 48.5%
Other Female Genitals 30.1% 29.5% 30.2% 31.1% 28.5% 28.0%
Prostate 7.2% 6.9% 7.2% 8.4% 6.1% 5.8%
Kidney 9.3% 8.9% 9.7% 3.3% 13.5% 9.0%
Bladder 32.3% 27.8% 33.2% 26.3% 32.5% 19.0%
Brain and CNS 38.2% 35.8% 38.6% 39.9% 32.3% 32.2%
Thyroid & other endocrine glands 5.5% 5.2% 5.6% 4.3% 8.1% 2.8%
CUP 11.2% 8.9% 11.8% 9.5% 9.0% 5.3%
Other invasive cancer 29.5% 27.8% 29.8% 28.5% 26.7% 26.2%
Breast in situ 2.2% 2.5% 2.2% 1.3% 1.4% 5.3%
Cervix in situ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Other tumours 14.4% 11.1% 15.5% 12.8% 9.5% 6.7%
Non-Melanoma Skin Cancer 0.1% 0.3% 0.1% 0.5% 0.1% 0.5%

% of Cases for other treatments
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
% of Cases treated with Hormone Therapy
All invasive xnmsc 12.7% 13.9% 12.3% 15.8% 9.8% 17.7%
Breast 39.4% 46.8% 37.2% 63.1% 24.0% 63.1%
Prostate 47.8% 50.8% 47.3% 53.5% 43.0% 59.5%
% of Cases treated with Brachytherapy
All invasive xnmsc 1.3% 1.2% 1.3% NA 1.1% 1.3%
Breast 0.1% 0.0% 0.1% NA 0.0% 0.0%
Prostate 2.4% 2.0% 2.5% NA 0.4% 3.0%
% of Cases treated with Watch & Wait/Active Monitoring
All invasive xnmsc 8.3% 8.1% 8.4% NA 8.5% 7.6%
Prostate 25.5% 24.1% 25.5% NA 26.3% 20.3%
% of Cases treated with Palliative Care
All invasive xnmsc 9.2% 8.4% 9.4% NA 6.0% 9.9%

Specific cohorts where treatment completeness data is expected (%)
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
% of children and young adults (0-24 group) with cancer & underwent any treatment 95.0% 90.8% 95.8% 91.9% 94.4% 81.0%
% of all stage 1 cancer patients who received any treatment 93.9% 87.5% 95.3% 82.8% 92.7% 79.2%
% of men under 60 with prostate cancer & received hormone treatment 23.2% 28.6% 22.0% 32.1% 23.3% 37.1%
% of men under 60 with cancer (C00-C97 exc. C44) & received hormone treatment 4.3% 5.0% 4.1% 5.3% 4.1% 6.5%
% of women under 60 with breast cancer & received hormone treatment 25.8% 33.7% 23.4% 48.1% 11.0% 52.5%
% of all haematological cancer patients who received any treatment 81.9% 66.3% 85.0% 62.2% 79.1% 39.0%

Quality of treatment data
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
Surgery (denominator - all tumours known to be treated with surgery, first recorded surgery for that tumour):
Date of surgery known 99.8% 100.0% 99.8% 100.0% 100.0% 100.0%
Trust / hospital of surgery known 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Type of surgery known (OPCS4 code) 100.0% 100.0% 100.0% NA 100.0% 100.0%
Teletherapy (denominator - all tumours known to be treated with teletherapy, first recorded teletherapy treatment for that tumour):
Date of teletherapy known 100.0% 100.0% 100.0% NA 100.0% 100.0%
Trust / hospital of teletherapy known 100.0% 100.0% 100.0% NA 100.0% 100.0%
Fractions and dose known 95.5% 94.9% 95.6% NA 100.0% 89.0%
Chemotherapy (denominator - all tumours known to be treated with chemotherapy, first recorded chemotherapy treatment for that tumour):
Date of chemotherapy known 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Trust / hospital of chemotherapy known 99.9% 100.0% 99.9% 100.0% 100.0% 100.0%
Drug name or regimen known 78.1% 91.5% 76.3% NA 100.0% 98.3%
Radiotherapy (denominator - all tumours known to be treated with radiotherapy, take the first recorded radiotherapy event for that tumour):
Date of radiotherapy known 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Trust / hospital of radiotherapy known 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%

Breast cancer screening completeness (%)
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
Breast cancer - % screen detected for ages 50-64 (data 2017) 48.9% 50.8% 48.4% 50.1% 53.9% NA
Breast cancer - % screen detected for ages 50-64 (last year, 2016) 42.2% 48.2% 40.8% 48.0% 55.8% NA
Breast cancer - % with full screening history for ages 50-64 (data 2017) 93.9% 95.5% 93.2% 99.9% 93.4% NA
Breast cancer - % with full screening history for ages 50-64 (last year, 2016) 79.5% 87.4% 76.8% 100.0% 85.4% NA

Cervical cancer screening completeness (%)
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
Cervical cancer - % screen detected for ages 25-60 (data 2017) 17.8% 31.9% 14.2% 49.5% NA NA
Cervical cancer - % screen detected for ages 25-60 (last year, 2016) 28.6% 38.0% 25.6% 50.4% NA NA
Cervical cancer - % with full screening history for ages 25-60 (data 2017) 57.1% 76.1% 52.3% 100.0% NA NA
Cervical cancer - % with full screening history for ages 25-60 (last year, 2016) 67.5% 81.5% 63.1% 100.0% NA NA

Bowel cancer screening completeness (%)
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
Bowel cancer - % screen detected for ages 60-69 (data 2017) 4.5% 19.5% 0.0% 29.4% 29.1% NA
Bowel cancer - % screen detected for ages 60-69 (last year, 2016) 4.4% 19.2% 0.0% 29.2% 28.4% NA
Bowel cancer - % with full screening history for ages 60-69 (data 2017) 15.4% 66.6% 0.0% 100.0% 99.8% NA
Bowel cancer - % with full screening history for ages 60-69 (last year, 2016) 15.3% 66.6% 0.0% 99.7% 100.0% NA

Completeness of the dataset (%) - stage complete by cancer site groups summary (persons)
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 80.6% 78.6% 81.9% 67.5% 79.7% 85.3%
Haematology 65.3% 52.1% 70.4% 0.0% 61.7% 76.3%
Head and Neck 89.1% 88.6% 90.5% 74.5% 91.4% 97.9%
Lower GI 88.6% 87.0% 89.8% 74.6% 91.9% 91.6%
Upper GI 82.7% 79.6% 83.9% 72.8% 86.8% 74.9%
HPB 73.1% 73.2% 73.5% 72.2% 63.6% 83.3%
Bronchus & Lung 93.1% 92.5% 93.5% 89.8% 93.5% 93.2%
Melanoma of skin 89.6% 80.0% 94.0% 38.4% 89.7% 98.0%
Breast 92.5% 90.4% 93.6% 84.2% 85.7% 98.0%
Cervix 92.1% 95.6% 91.2% 95.7% 97.1% 98.5%
Other Female Genitals 86.8% 86.6% 87.6% 75.6% 88.5% 94.6%
Prostate 90.0% 89.5% 90.3% 83.9% 92.2% 91.7%
Bladder 85.4% 81.0% 87.5% 63.3% 83.9% 89.2%
Kidney 85.2% 83.5% 86.2% 77.1% 77.7% 93.0%
Thyroid and other endocrine glands 76.9% 81.0% 76.3% 75.1% 75.4% 97.1%
Other invasive cancer 62.0% 53.9% 66.1% 21.1% 58.0% 70.3%
Non-Melanoma Skin Cancer 3.2% 6.4% 3.0% 0.0% 3.4% 19.2%

Completeness of the dataset (%) - grade complete by cancer site groups summary (persons)
Country average (population) Country average (country) England Scotland Northern Ireland Wales1 Republic of Ireland
All invasive xnmsc 59.6% 61.3% 59.4% 59.0% 61.1% 65.6%
All xnmsc 0-24 30.3% 38.3% 28.6% 38.3% 31.3% 55.2%
All xnmsc 25-59 67.3% 69.3% 66.8% 69.4% 68.9% 72.2%
All xnmsc 60-79 64.0% 65.3% 63.9% 63.0% 65.5% 68.9%
All xnmsc 80+ 41.9% 43.0% 42.0% 37.7% 43.3% 48.8%
All registrations 44.5% 44.3% 44.5% 45.0% 44.0% 43.8%
Haematology 15.2% 34.0% 11.8% 33.9% 11.0% 79.2%
Head and Neck 80.9% 84.0% 80.1% 82.8% 86.7% 86.5%
Lower GI 79.7% 79.3% 79.8% 78.8% 80.3% 78.1%
Upper GI 78.2% 76.2% 78.9% 74.3% 78.9% 72.8%
HPB 28.7% 25.1% 29.8% 20.9% 25.5% 24.1%
Trachea, Bronchus & Lung 27.5% 27.6% 27.3% 27.8% 31.0% 24.3%
Melanoma of skin 0.8% 0.8% 0.8% 0.7% 1.5% 0.0%
Breast 96.4% 95.9% 96.6% 94.6% 96.5% 95.9%
Cervix 81.0% 81.0% 80.8% 83.3% 81.2% 78.8%
Other Female Genitals 76.0% 77.5% 75.8% 75.8% 78.2% 80.3%
Prostate 82.6% 82.8% 82.6% 80.5% 84.8% 83.4%
Kidney 60.5% 61.0% 60.8% 56.0% 58.2% 69.0%
Bladder 85.4% 85.6% 85.5% 84.1% 85.4% 87.4%
Brain and CNS 69.8% 74.3% 69.6% 68.5% 60.9% 98.0%
Thyroid and other endocrine glands 20.1% 14.1% 21.6% 9.2% 16.9% 8.5%
CUP 21.6% 19.5% 22.0% 18.0% 24.3% 13.6%
Other invasive cancer 31.6% 31.1% 31.9% 27.5% 33.0% 31.8%
Other tumours 34.2% 24.4% 38.8% 17.4% 35.4% 6.0%
Non-Melanoma Skin Cancer 29.1% 31.7% 28.7% 32.7% 23.7% 41.7%

1 Data for Wales is on the preceding year.